SlidesetViral Hepatitis and Liver DiseaseAnti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel VerdonView Slideset
SlidesetViral Hepatitis and Liver DiseaseRationale for Modulating Adaptive Immunity: Therapeutic Vaccination, Checkpoint Inhibitor and others | Robert ThimmeView Slideset
SlidesetViral Hepatitis and Liver DiseaseClinical progress of the entry inhibitor Myrcludex B | Stephan UrbanView Slideset
SlidesetViral Hepatitis and Liver DiseaseRationale for different Virological Targets in HBV | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Slideset
SlidesetViral Hepatitis and Liver DiseaseClinical update on reducing HBV virus and antigen production using RNAi | Bruce GivenView Slideset
SlidesetViral Hepatitis and Liver DiseaseClinical update, antiviral effect and mode of action of capsid assembly modulators | Jeysen YogaratnamView Slideset
SlidesetViral Hepatitis and Liver DiseaseEstablishing functional control of HBV and HDV infection with REP 2139-based combination therapy | Andrew VaillantView Slideset
SlidesetViral Hepatitis and Liver DiseaseTargeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates | Richard ColonnoView Slideset
SlidesetViral Hepatitis and Liver DiseaseWhat is the cure rate with current therapies? | Harry Janssen, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseImmune reconstitution with current available antiviral therapies: a baseline to gauge new immunotherapies | Andre BoonstraView Slideset
SlidesetViral Hepatitis and Liver DiseaseStopping Nucleos(t)ide Analogues: When is it beneficial, when is it dangerous? | Thomas Berg, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseWill HBsAg depletion restore HBV specific immunity? | Adam Gehring, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseWhat are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPHView Slideset
SlidesetViral Hepatitis and Liver DiseaseAntiviral effect of the RIG-I agonist, Inarigavir | Nezam AfdahlView Slideset
SlidesetViral Hepatitis and Liver DiseaseRationale for modulating innate immunity: TLR, RIG- and others | Mala Maini, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseCombination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model | Yonghong ZhuView Slideset
SlidesetViral Hepatitis and Liver DiseaseInnate activation with Inactivated parapox viruses for HBV therapy - AIC649 | Daniela PaulsenView Slideset
